Drugs & Therapy Perspectives

, Volume 34, Issue 8, pp 402–403 | Cite as

Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report

  • Elda RighiEmail author
  • Daniele Muser
  • Alessia Carnelutti
  • Federico Pea
  • Assunta Sartor
  • Matteo Bassetti
Short Communication


Candida endocarditis represents a life-threatening infection with high mortality rates despite adequate antifungal treatment. Step-down oral treatment with fluconazole or voriconazole represents a treatment option for clinically stable patients. Drug toxicity, however, is reported during azole therapy and can be challenging, especially among patients with multiple comorbidities. This is the first report that highlights the impact of isavuconazole on the corrected QT interval and liver toxicity in a cirrhotic patient with Candida endocarditis.


Compliance with ethical standards

Informed consent

Informed written consent was obtained from the patient for the publication of this case report.

Conflict of interest

All authors declare that they have no potential conflicts of interest.


No specific funding was received.


  1. 1.
    Lefort A, Chartier L, Sendid B, et al; On behalf of the French Mycosis Study Group. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18(4):E99–E109.Google Scholar
  2. 2.
    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.CrossRefGoogle Scholar
  3. 3.
    Allen D, Wilson D, Drew R, et al. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Antiinfect Ther. 2015;13:787–98.CrossRefGoogle Scholar
  4. 4.
    Weiler S, Zoller H, Graziadei I, et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother. 2007;9:3459–60.CrossRefGoogle Scholar
  5. 5.
    Keirns J, Desai A, Kowalski D, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101:782–90.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Infectious Diseases DivisionSanta Maria della Misericordia University HospitalUdineItaly
  2. 2.Department of CardiologySanta Maria della Misericordia University HospitalUdineItaly
  3. 3.Institute of Clinical PharmacologySanta Maria della Misericordia University Hospital, University of UdineUdineItaly
  4. 4.Department of MedicineUniversity of UdineUdineItaly
  5. 5.Division of MicrobiologySanta Maria della Misericordia University HospitalUdineItaly

Personalised recommendations